Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/pharmacogenomics-patent-landscape-patent-landscape/ · Patsnap · data cut-off 2026-08-31 · downloaded from the live page
Patent Landscape · Genomics, Omics & BioinformaticsPharmacogenomics patents: mapping the field's leaders, filing trends and open claim space
- 16.8% concentration. The five leading assignees hold 7,205 of 42,997 records in scope — a real lead, but not a lock on the field.
- A long tail beyond the top 10. Combined, the ten leading assignees account for 24.9% of records, meaning three-quarters of filings sit outside the ranked leaders.
- Filing pace off its 2018 peak. From 359 filings in 2021 to 145 in 2024 — a 60% drop over that span — though the two most recent years are still filling in as publications lag filing.
43K
Published Records
17%
Top-5 Share of All Records
-60%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (359 records) with 2024 (145) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 42,997 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What the pharmacogenomics patent record shows
Pharmacogenomics sits at the intersection of drug response biology and sequence-level molecular analysis, and the patent record reflects that split. Records in scope span nucleic acid amplification and sequencing methods, expression-level and biomarker detection, and peptide and protein compositions tied to therapeutic response. The 2018 peak in filings coincides with a period of heavy sequencing-method and biomarker-detection activity; the more recent decline reflects publication lag as much as any pullback in R&D.
The technology composition below is class-weighted rather than record-exclusive: a single filing can carry claims across measuring/testing, genetic engineering and therapeutic-activity classes at once, so the shares do not sum to 100%.
Filing activity and technology composition, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Pharmacogenomics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Data
Filing trends and technology composition
42,997 records published between 2015 and the 2026 cut-off, spread across sequencing methods, genetic engineering and analytical detection classes.
Filing trend, 2017–2026
Filings ran from 362 in 2017 to a peak of 404 in 2018, then eased to 145 by 2024, a 60% drop from the 359 filed in 2021. The 2025 and 2026 figures (down to 17) are undercounts: publication typically lags filing by around 18 months, so recent years will continue to fill in.
Technology composition by IPC subclass
C12Q (measuring and testing involving enzymes or DNA) leads at 27.0% of the 42,997 records in scope, followed by C12N (microorganisms and genetic engineering) at 24.8% and A61K (medicinal preparations) at 20.1%. C07H (sugars and nucleic acids), the smallest class shown at 6.0%, marks a comparatively lighter-filed adjacency to the sequencing-heavy core.
Shares are the percentage of the 42,997 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Pharmacogenomics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Pharmacogenomics Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about pharmacogenomics patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The patents other filings build on
Representative filing
US20230055466A1 — A method of nucleic acid sequence analysis
INVIVOSCRIBE, INC.
Methods of analysing nucleotide read sequences from a nucleic acid sample using high-throughput bidirectional sequencing, designed to work even where forward and reverse reads are too short to pair through overlapping 3' end hybridisation, together with computer-implemented methods for preparing non-overlapping sequence reads for downstream screening.Filed by Invivoscribe, published 2023-02-23.
Most-cited records in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7115400B1 | Methods of nucleic acid amplification and sequencing | 2,274 |
| 2 | WO2000018957A1 | Methods of nucleic acid amplification and sequencing | 1,414 |
| 3 | WO2002032962A2 | Compositions of human proteins and method of use thereof | 1,050 |
| 4 | US6251639B1 | Methods and compositions for linear isothermal amplification of polynucleotide sequences, using a RNA-DNA com… | 958 |
| 5 | US6812339B1 | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof | 926 |
| 6 | US20040096853A1 | Isothermal amplification of nucleic acids on a solid support | 924 |
| 7 | US6858412B2 | Direct multiplex characterization of genomic DNA | 738 |
| 8 | US20210090694A1 | Data based cancer research and treatment systems and methods | 715 |
| 9 | US6664079B2 | Massive parallel method for decoding DNA and RNA | 625 |
| 10 | US20070083334A1 | Methods and systems for annotating biomolecular sequences | 557 |
Citation counts favour older filings simply because they have had more time to accumulate references — read them as a signal of influence on the field's method vocabulary, not of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Pharmacogenomics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for strategy
Three patterns worth acting on: where filing has concentrated, where it has cooled, and where citation weight sits relative to filing recency.
Concentration
16.8%
of 42,997 records held by top 5
Leadership is real but not dominant
The five leading assignees hold 7,205 records, 16.8% of the field. That leaves the large majority of filings distributed across a long tail of single- and few-filing entrants, which is typical of a field built on method and biomarker claims rather than a single platform patent.
Read against the full ranked list, not a top-100 assumption.
Filing pace
-60%
2021 to 2024 (359 → 145 filings)
Momentum has cooled from the 2018 peak
Filing volume dropped 60% between 2021 and 2024. That decline should not be read past 2024: publication lag of roughly 18 months means 2025 and 2026 figures are still incomplete and will rise as more records post.
Treat 2025-2026 counts as provisional.
Citation weight
2,274 citations
on the single most-cited record
Influence skews toward older sequencing-method patents
The most-cited record in scope, on nucleic acid amplification and sequencing methods, carries 2,274 citations — more than any other filing by a wide margin. That weight reflects age and foundational method claims, not that the technique remains the most actively filed today.
Cross-check citation leaders against recent filing activity before assuming continued relevance.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to pharmacogenomics patent landscape, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Pharmacogenomics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who holds the claim space
The ranked list covers 100 companies measured in records, led by a filer at 3,279 records with the fifth-place holder at 859 and the tenth at 535 — a steep drop-off that signals a small set of pharma and diagnostics filers followed by a broad field of smaller entrants.
Leader
3,279 records
leading assignee
One filer sits well ahead of the field
The top-ranked assignee holds 3,279 records, more than triple the fifth-place holder's 859. That gap is typical of an early-mover advantage in sequencing and expression-analysis methods built up over multiple filing waves.
Gap narrows quickly after position five.
Mid-pack
859 → 535
fifth to tenth place
Positions five to ten cluster closely
Records fall from 859 at fifth place to 535 at tenth, a much gentler slope than the drop from first to fifth. This is where diagnostics and pharma companies with sustained but not dominant pharmacogenomics programmes sit.
Ten combined assignees hold 24.9% of all records.
Recent momentum
0 in latest year
for several historic leaders
Some historic leaders show no recent-year filings
Several assignees prominent in the overall ranking recorded zero filings in the latest year tracked, consistent with the broader cooling in filing pace and with corporate consolidation among early pharmacogenomics specialists.
Check current assignee status before assuming continued activity.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Millennium Pharmaceuticals, Inc. | 0 | — |
| CURAGEN CORP | 0 | — |
| Applera Corporation | 0 | — |
| Applera Corporation | 0 | — |
| Lexicon Pharmaceuticals, Inc. | 0 | — |
| Agensys, Inc. | 0 | — |
| SHIMKETS RICHARD A | 0 | — |
| SPYTEK KIMBERLY A | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Pharmacogenomics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking or identifying open filing space.
Check freedom-to-operate against the cited leaders
Before filing in sequencing-method or expression-biomarker claims, screen against the most-cited records in this dataset, which anchor much of the method vocabulary still referenced in newer filings.
Run a freedom-to-operate check in EurekaWatch the assignees with zero recent filings
Several historically prominent filers show no activity in the latest tracked year. That can mean consolidation, licensing-out, or a shift to trade secrecy — worth confirming before assuming the space is open.
Track assignee activity in EurekaTest claim language against under-claimed branches
Fermentation-based biomarker synthesis and sugar-nucleic acid conjugate claims carry lighter filing density than the sequencing core. Drafting around these adjacencies may face less prior art.
Explore white space in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Pharmacogenomics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on pharmacogenomics patents
The ranked list in this dataset covers 100 assignees measured by patent family records, with the leading filer holding 3,279 records, well ahead of the fifth-place holder at 859. Filing is concentrated at the top but not dominated by a single company: the five leading assignees together hold 16.8% of all 42,997 records in scope, meaning the large majority of filings come from a long tail of smaller and single-filing entrants. Anyone benchmarking a competitive position should look at both the leader gap and the size of that tail, since the tail is where new entrants typically appear.
Filing volume peaked in 2018 at 404 records and has since declined, falling 60% between 2021 (359 filings) and 2024 (145 filings), the most recent year that can be treated as complete. Figures for 2025 and 2026 look lower still, but that is expected: publication typically lags actual filing by around 18 months, so the most recent one to two years are always undercounted at the point of any given data pull. The honest read is that filing pace has cooled from its 2018 peak, not that it has stopped.
By IPC subclass, C12Q (measuring and testing involving enzymes or DNA) leads at 27.0% of the 42,997 records in scope, followed closely by C12N (genetic engineering and microorganisms) at 24.8% and A61K (medicinal preparations) at 20.1%. Peptide and protein claims (C07K) and material analysis methods (G01N) also carry meaningful shares, at 19.4% and 15.4% respectively. Because a single record can carry claims across multiple classes, these percentages add up to more than 100% and should not be treated as mutually exclusive slices of the field.
US20230055466A1, filed by Invivoscribe and published in February 2023, covers methods for analysing nucleotide read sequences using high-throughput bidirectional sequencing, specifically addressing cases where forward and reverse reads are too short to pair through standard overlap hybridisation. It also claims computer-implemented methods for preparing non-overlapping sequence reads for downstream screening. Anyone building short-read sequencing pipelines for pharmacogenomic biomarker analysis with reads that fail to overlap at the 3' end should review this filing's specific claim language before designing a workaround.
Filing density is lightest, relative to the sequencing and genetic-engineering core, in fermentation-based biomarker synthesis (C12P, 7.2% of records) and sugar-nucleic acid conjugate claims (C07H, 6.0% of records). Multi-marker expression-panel scoring and cross-jurisdiction filing gaps between PCT applications and national-phase entry also show room for new claims. These are not gaps in scientific interest, only in claim density, so a novelty search specific to the intended claim language is still essential before filing.
Answers are grounded in the same dataset. Derived from a Patsnap search on Pharmacogenomics Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Pharmacogenomics Patent Landscape in depth with Eureka
Go past this page: query the whole pharmacogenomics patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.